MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. [electronic resource]
Producer: 20071030Description: 2092-101 p. digitalISSN:- 0006-4971
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Apoptosis Regulatory Proteins -- antagonists & inhibitors
- Bcl-2-Like Protein 11
- Benzamides -- pharmacology
- Blotting, Western
- Drug Synergism
- Enzyme Inhibitors -- pharmacology
- Humans
- Immunoprecipitation
- Insulin-Like Growth Factor I -- pharmacology
- Interleukin-6 -- pharmacology
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- MAP Kinase Kinase 2 -- antagonists & inhibitors
- Membrane Proteins -- antagonists & inhibitors
- Multiple Myeloma -- drug therapy
- Phosphorylation -- drug effects
- Protein Conformation
- Protein Kinase C -- antagonists & inhibitors
- Protein Transport
- Proto-Oncogene Proteins -- antagonists & inhibitors
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- RNA, Small Interfering -- pharmacology
- Staurosporine -- analogs & derivatives
- Subcellular Fractions
- bcl-2 Homologous Antagonist-Killer Protein -- metabolism
- bcl-2-Associated X Protein -- metabolism
- bcl-X Protein -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.